Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - PATTERSON COMPANIES, INC.Financial_Report.xls
EX-32 - EX-32 - PATTERSON COMPANIES, INC.d769178dex32.htm
EX-31.2 - EX-31.2 - PATTERSON COMPANIES, INC.d769178dex312.htm
EX-31.1 - EX-31.1 - PATTERSON COMPANIES, INC.d769178dex311.htm
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED July 26, 2014.

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File No. 0-20572

 

 

PATTERSON COMPANIES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Minnesota   41-0886515

(State of

incorporation)

 

(I.R.S. Employer

Identification Number)

1031 Mendota Heights Road

St. Paul, Minnesota

  55120
(Address of principal executive offices)   (Zip Code)

(651) 686-1600

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer   x    Accelerated Filer   ¨
Non-Accelerated Filer   ¨    Smaller Reporting Company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of August 28, 2014, there were 104,259,810 shares of Common Stock of the registrant issued and outstanding.

 

 

 


Table of Contents

PATTERSON COMPANIES, INC.

INDEX

 

     Page  

PART I - FINANCIAL INFORMATION

  

Item 1- Financial Statements (Unaudited)

     3-12   

Condensed Consolidated Balance Sheets as of July 26, 2014 and April 26, 2014

     3   

Condensed Consolidated Statements of Income and Other Comprehensive Income for the Three Months Ended July  26, 2014 and July 27, 2013

     4   

Condensed Consolidated Statements of Cash Flows for the Three Months Ended July 26, 2014 and July  27, 2013

     5   

Notes to Condensed Consolidated Financial Statements

     6-12   

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations

     13-15   

Item 3 - Quantitative and Qualitative Disclosures about Market Risk

     16   

Item 4 - Controls and Procedures

     16   

PART II - OTHER INFORMATION

  

Item 5 - Unregistered Sales of Equity Securities and Use of Proceeds

     16   

Item 6 - Exhibits

     16   

Signatures

     17   

Exhibit Index

     18   

Safe Harbor Statement under The Private Securities Litigation Reform Act of 1995:

This Form 10-Q for the period ended July 26, 2014, contains certain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, which may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “anticipate”, “estimate”, “believe”, “goal”, or “continue”, or comparable terminology that involves risks and uncertainties that are qualified in their entirety by cautionary language set forth herein under the caption “Factors That May Affect Future Operating Results,” in our 2014 Annual Report on Form 10-K filed June 25, 2014 and other documents previously filed with the Securities and Exchange Commission.

 

2


Table of Contents

PART I—FINANCIAL INFORMATION

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

 

     July 26,     April 26,  
     2014     2014  
     (Unaudited)        

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 260,740      $ 264,908   

Short-term investments

     41,607        40,775   

Receivables, net

     564,458        607,580   

Inventory

     518,857        436,463   

Prepaid expenses and other current assets

     59,524        65,991   
  

 

 

   

 

 

 

Total current assets

     1,445,186        1,415,717   

Property and equipment, net

     214,453        204,939   

Long-term receivables, net

     88,335        90,535   

Goodwill

     845,124        844,433   

Identifiable intangibles, net

     219,287        223,150   

Other

     86,787        85,903   
  

 

 

   

 

 

 

Total assets

   $ 2,899,172      $ 2,864,677   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current liabilities:

    

Accounts payable

   $ 388,171      $ 342,056   

Accrued payroll expense

     45,166        66,567   

Other accrued expense

     149,629        134,840   
  

 

 

   

 

 

 

Total current liabilities

     582,966        543,463   

Long-term debt

     725,000        725,000   

Other

     123,105        124,550   
  

 

 

   

 

 

 

Total liabilities

     1,431,071        1,393,013   

Stockholders’ equity:

    

Common stock

     1,029        1,040   

Additional paid-in capital

     —          —     

Accumulated other comprehensive income

     33,371        25,370   

Retained earnings

     1,519,645        1,531,198   

Unearned ESOP shares

     (85,944     (85,944
  

 

 

   

 

 

 

Total stockholders’ equity

     1,468,101        1,471,664   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 2,899,172      $ 2,864,677   
  

 

 

   

 

 

 

See accompanying notes.

 

3


Table of Contents

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

AND OTHER COMPREHENSIVE INCOME

(In thousands, except per share amounts)

(Unaudited)

 

     Three Months Ended  
     July 26,     July 27,  
     2014     2013  

Net sales

   $ 1,059,529      $ 880,125   

Cost of sales

     763,304        598,607   
  

 

 

   

 

 

 

Gross profit

     296,225        281,518   

Operating expenses

     211,471        200,237   
  

 

 

   

 

 

 

Operating income

     84,754        81,281   

Other income and expense:

    

Other income, net

     1,502        (557

Interest expense

     (8,768     (8,567
  

 

 

   

 

 

 

Income before taxes

     77,488        72,157   

Income taxes

     27,199        26,265   
  

 

 

   

 

 

 

Net income

   $ 50,289      $ 45,892   
  

 

 

   

 

 

 

Earnings per share:

    

Basic

   $ 0.51      $ 0.45   
  

 

 

   

 

 

 

Diluted

   $ 0.50      $ 0.45   
  

 

 

   

 

 

 

Weighted average common shares:

    

Basic

     99,329        101,027   
  

 

 

   

 

 

 

Diluted

     100,182        101,919   
  

 

 

   

 

 

 

Dividends declared per common share

   $ 0.20      $ 0.16   
  

 

 

   

 

 

 

Other Comprehensive Income

    

Net income

   $ 50,289      $ 45,892   

Foreign currency translation gain / (loss)

     10,310        (8,306

Cash flow hedge loss

     (2,309     (48
  

 

 

   

 

 

 

Comprehensive Income

   $ 58,290      $ 37,538   
  

 

 

   

 

 

 

See accompanying notes.

 

4


Table of Contents

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

     Three Months Ended  
     July 26,     July 27,  
     2014     2013  

Operating activities:

    

Net income

   $ 50,289      $ 45,892   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation

     6,699        6,580   

Amortization

     4,792        4,396   

Bad debt expense

     478        244   

Non-cash employee compensation

     6,412        4,462   

Excess tax benefits from stock-based compensation

     (512     (553

Change in assets and liabilities, net of acquired

     612        (39,896
  

 

 

   

 

 

 

Net cash provided by operating activities

     68,770        21,125   

Investing activities:

    

Additions to property and equipment, net

     (16,681     (5,564

Proceeds from sale of assets

     5,594        —     

Purchase of investments

     (359     —     
  

 

 

   

 

 

 

Net cash used in investing activities

     (11,446     (5,564

Financing activities:

    

Dividends paid

     (20,062     (29,773

Repurchases of common stock

     (42,877     (22,199

Payment on revolver

     (130,000     —     

Draw on revolver

     130,000        135,000   

Other financing activities

     (811     1,732   
  

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     (63,750     84,760   

Effect of exchange rate changes on cash

     2,258        (2,180
  

 

 

   

 

 

 

Net decrease in cash and cash equivalents

     (4,168     98,141   

Cash and cash equivalents at beginning of period

     264,908        505,228   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 260,740      $ 603,369   
  

 

 

   

 

 

 

See accompanying notes.

 

5


Table of Contents

PATTERSON COMPANIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share and per share data)

(Unaudited)

July 26, 2014

NOTE 1 GENERAL

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of our Company as of July 26, 2014, and our results of operations and cash flows for the periods ended July 26, 2014 and July 27, 2013. Such adjustments are of a normal recurring nature. The results of operations for the periods ended July 26, 2014 and July 27, 2013, are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the financial statements included in the 2014 Annual Report on Form 10-K filed on June 25, 2014.

The condensed consolidated financial statements of Patterson Companies, Inc. (“Patterson” or “Company”) include the assets and liabilities of PDC Funding Company, LLC (“PDC Funding”) and PDC Funding Company II, LLC (“PDC Funding II”), wholly owned subsidiaries and separate legal entities under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities of our Company established to sell customer installment sale contracts to outside financial institutions in the normal course of business. The assets of PDC Funding and PDC Funding II would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding or PDC Funding II.

Fiscal Year End

The fiscal year end of our Company is the last Saturday in April. The first quarter of fiscal years 2015 and 2014 represents the 13 weeks ended July 26, 2014 and July 27, 2013, respectively. Fiscal years 2015 and 2014 each include 52 weeks of operations.

Comprehensive Income

Comprehensive income is computed as net income plus certain other items that are recorded directly to stockholders’ equity. Significant items included in comprehensive income are foreign currency translation adjustments and the effective portion of cash flow hedges. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S.

Earnings Per Share

The following table sets forth the computation of the weighted average shares outstanding used to calculate basic and diluted earnings per share (shares in thousands):

 

     Three Months Ended  
     July 26,
2014
     July 27,
2013
 

Denominator:

     

Denominator for diluted earnings per share—weighted average shares

     99,329         101,027   

Effect of dilutive securities—stock options, restricted stock, ESOP and stock purchase plans

     853         892   
  

 

 

    

 

 

 

Denominator for diluted earnings per share—adjusted weighted average shares

     100,182         101,919   
  

 

 

    

 

 

 

Options to purchase 2,000 shares of common stock during the three months ended July 26, 2014, and 148,000 shares during the three months ended July 27, 2013, respectively, were excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive. There were no unvested restricted stock awards excluded from the calculation of diluted earnings per share during the three months ended July 26, 2014, or the three months ended July 27, 2013, respectively, because the effect would have been anti-dilutive.

 

6


Table of Contents

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. ASU No. 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605),” and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. We are evaluating the new standard, but do not, at this time, anticipate a material impact to the financial statements once implemented.

NOTE 2 ACQUISITIONS

On August 16, 2013, Patterson Companies, Inc. completed the acquisition of all the outstanding stock of National Veterinary Services Limited (“NVS”) from Dechra Pharmaceuticals, PLC. NVS is the largest veterinary products distributor in the United Kingdom.

Operating results for this acquisition have been included in our Condensed Consolidated Statements of Income and Other Comprehensive Income from the date of acquisition and are reflected in the Veterinary reporting segment. The acquisition contributed $173,576 of net sales to the segment for the first quarter. Pro forma results are not presented, as the acquisition is not considered material to our Company.

NOTE 3 GOODWILL AND OTHER INTANGIBLE ASSETS

The goodwill balances and related activity by business segment as of April 26, 2014 and July 26, 2014 are as follows:

 

            Acquisition      Translation         
     Balance at      Activity &      And Other      Balance at  
     April 26, 2014      Divestitures      Activity      July 26, 2014  

Dental Supply

   $ 137,463       $ 0       $ 242       $ 137,705   

Rehabilitation Supply

     545,007         0         187         545,194   

Veterinary Supply

     161,963         0         262         162,225   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 844,433       $ 0       $ 691       $ 845,124   
  

 

 

    

 

 

    

 

 

    

 

 

 

Balances of other intangible assets excluding goodwill are as follows:

 

     July 26,     April 26,  
     2014     2014  

Unamortized—indefinite lived:

    

Copyrights, trade names and trademarks

   $ 76,464      $ 76,464   

Amortized:

    

Distribution agreement, customer lists and other

     287,480        286,365   

Less: Accumulated amortization

     (144,657     (139,679
  

 

 

   

 

 

 

Net amortized other intangible assets

     142,823        146,686   
  

 

 

   

 

 

 

Total identifiable intangible assets, net

   $ 219,287      $ 223,150   
  

 

 

   

 

 

 

NOTE 4 DERIVATIVE FINANCIAL INSTRUMENTS

Patterson is a party to certain offsetting and identical interest rate cap agreements. These cap agreements are not designated for hedge accounting treatment and were entered into to fulfill certain covenants of a sale agreement between a commercial paper conduit managed by The Bank of Tokyo-Mitsubishi UFJ, Ltd. and PDC Funding. On December 5, 2013, this agreement was amended on terms consistent with the expiring agreement. The cap agreements provide a credit enhancement feature for the financing contracts sold by PDC Funding to the commercial paper conduit.

The cap agreements are cancelled and new agreements entered into periodically to maintain consistency with the dollar maximum of the sale agreements and the maturity of the underlying financing contracts. As of July 26, 2014, PDC Funding had purchased an interest rate cap from a bank with a notional amount of $500,000 and a maturity date of February 2022. Patterson Companies, Inc. sold an identical interest rate cap to the same bank.

 

7


Table of Contents

Similar to the above agreements, PDC Funding II, and Patterson Companies, Inc. entered into offsetting and identical interest rate cap agreements with a notional amount of $75,000 in fiscal 2013. In August 2013, these agreements were terminated and replaced with offsetting and identical interest rate cap agreements. The notional amount increased to $100,000 and the new maturity date is January 2021.

In addition to the identical purchased and sold interest rate cap agreements described above, in May 2012 we entered into an interest rate swap agreement with a bank to economically hedge the interest rate risk associated with a portion of the finance contracts we had sold through the special purpose entities.

These interest rate contracts do not qualify for hedge accounting treatment and, accordingly, we record the fair value of the agreements as an asset or liability and the change as income or expense during the period in which the change occurs.

In January 2014 we entered into a forward interest rate swap agreement with a notional amount of $250,000 and accounted for as cash flow hedge, to hedge interest rate fluctuations in anticipation of refinancing the 5.17% senior notes due March 25, 2015 with a long-term loan for $250,000 and a term of ten years.

The following presents the fair value of interest rate contracts included in the consolidated balance sheets:

 

          July 26,      April 26,      July 27,  
Derivative type   

Classification

   2014      2014      2013  

Assets:

     

Interest rate contracts

   Other noncurrent assets    $ 1,222       $ 1,716       $ 1,153   

Liabilities:

           

Interest rate contracts

   Other noncurrent liabilities    $ 1,224       $ 1,720       $ 1,167   

Interest rate swap

   Other current liabilities    $ 12,734       $ 5,660       $ —     

The following table presents the effect of interest rate contracts on the consolidated statements of income and other comprehensive income (net of tax):

 

          Three Months Ended  
          July 26,
2014
     July 27,
2013
 

Interest rate contracts

   Other income (expense), net    $ 0       $ (4

Interest rate swap

   Other comprehensive Income      ($2,309)       $ (48

NOTE 5 FAIR VALUE MEASUREMENTS

Fair value is the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. The fair value hierarchy of measurements is categorized into one of three levels based on the lowest level of significant input used:

 

Level 1 -   Quoted prices in active markets for identical assets and liabilities at the measurement date.
Level 2 -   Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3 -   Unobservable inputs for which there is little or no market data available. These inputs reflect management’s assumptions of what market participants would use in pricing the asset or liability.

 

8


Table of Contents

Our hierarchy for assets and liabilities measured at fair value on a recurring basis as of July 26, 2014 is as follows:

 

    Total     Quoted Prices in Active
Markets (Level 1)
    Significant Other
Observable Inputs
(Level 2)
    Significant Unobservable
Inputs (Level 3)
 

Assets:

       

Cash equivalents

  $ 45,416      $ 45,416      $ —        $ —     

Derivative instruments

    1,222        —          1,222        —     
 

 

 

   

 

 

   

 

 

   

 

 

 

Total assets

  $ 46,638      $ 45,416      $ 1,222      $ —     
 

 

 

   

 

 

   

 

 

   

 

 

 

Liabilities:

       

Derivative instruments

  $ 13,958      $ —        $ 13,958      $ —     
 

 

 

   

 

 

   

 

 

   

 

 

 

Our hierarchy for assets and liabilities measured at fair value on a recurring basis as of April 26, 2014 is as follows:

 

    Total     Quoted Prices in Active
Markets (Level 1)
    Significant Other
Observable Inputs
(Level 2)
    Significant Unobservable
Inputs (Level 3)
 
       

Assets:

       

Cash equivalents

  $ 51,511      $ 51,511      $ —        $ —     

Derivative instruments

    1,716        —          1,716        —     
 

 

 

   

 

 

   

 

 

   

 

 

 

Total assets

  $ 53,227      $ 51,511      $ 1,716      $ —     
 

 

 

   

 

 

   

 

 

   

 

 

 

Liabilities:

       

Derivative instruments

  $ 7,380      $ —        $ 7,380      $ —     
 

 

 

   

 

 

   

 

 

   

 

 

 

Cash equivalents – We value cash equivalents at their current market rates. The carrying value of cash equivalents approximates fair value and maturities are less than three months.

Derivative instruments – Patterson’s derivative instruments consist of interest rate contracts. These instruments are valued using observable inputs such as interest rates and credit spreads.

Certain assets are measured at fair value on a non-recurring basis. These assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments under certain circumstances, such as when there is evidence of impairment. There were no fair value adjustments to such assets during the periods ended July 26, 2014 or July 27, 2013.

Patterson’s debt is not measured at fair value in the consolidated balance sheets. The estimated fair value of our debt as of July 26, 2014 and April 26, 2014 was $744,644 and $742,619, respectively. The fair value of debt was measured using a discounted cash flow analysis based on expected market based yields. These are considered to be Level 2 inputs under the fair value measurements and disclosure guidance.

The carrying amounts of receivables, net of allowances, accounts payable, and certain accrued and other current liabilities approximated fair value at July 26, 2014 and July 27, 2013.

NOTE 6 SECURITIES

On October 25th, 2013 we invested in three time deposits with total principal of $110,000 Canadian dollars. Our time deposit securities are classified as “held-to-maturity” securities as we have both the intent and ability to hold until maturity. They are carried at cost, adjusted for accrued interest and amortization. The

 

9


Table of Contents

current value is not materially different than fair value. The fair value was determined based on a discounted cash flow analysis using unobservable inputs (i.e. level 3 inputs), which include a forward yield curve, the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially lower fair value estimate. The interrelationship between these inputs is insignificant. The U.S. dollar equivalents at July 26, 2014, include $41,607, which is classified as a current asset and will mature within one year, and $60,099, which is classified as a noncurrent asset and will mature within two years.

NOTE 7 CUSTOMER FINANCING

As a convenience to our customers, we offer several different financing alternatives including both our Company-sponsored program and a third party program. For the third party program, we act as a facilitator between the customer and the third party financing entity with no on-going involvement in the financing transaction. Under our sponsored program, equipment purchased by customers with strong credit may be financed up to a maximum of $500 for any one customer. We generally sell the customers’ financing contracts to outside financial institutions in the normal course of our business. Patterson currently has two arrangements under which we sell these contracts.

Patterson operates under an agreement to sell a portion of our equipment finance contracts to commercial paper conduits with The Bank of Tokyo-Mitsubishi UFJ, Ltd. serving as the agent. We utilize a special purpose entity (“SPE”), PDC Funding, a consolidated, wholly owned subsidiary to fulfill a requirement of participating in the commercial paper conduit. We receive the proceeds of the contracts upon sale. At least 9% of the proceeds are held by the conduit as security against eventual performance of the portfolio. The amount held by the conduit can be greater than 9% and is based upon certain ratios defined in the agreement. The capacity under the agreement at July 26, 2014 was $500,000.

Patterson also maintains an agreement with Fifth Third Bank whereby the bank purchases customers’ financing contracts. Patterson has established another SPE, PDC Funding II, as a consolidated, wholly owned subsidiary, which sells financing contracts to the bank. We receive the proceeds of the contracts upon sale. At least 10% of the proceeds are held by the conduit as security against eventual performance of the portfolio. The amount held by the conduit can be greater than 10% and is based upon certain ratios defined in the agreement. The capacity under the agreement at July 26, 2014 was $100,000.

The portion of the purchase price for the receivables held by the conduits is a deferred purchase price receivable, which is paid to the SPE as payments on the receivables are collected from customers. The deferred purchase price receivable represents a beneficial interest in the transferred financial assets and is recognized at fair value as part of the sale transaction. The Company values the deferred purchase price receivable based on a discounted cash flow analysis using unobservable inputs (i.e. level 3 inputs), which include a forward yield curve, the estimated timing of payments and the credit quality of the underlying creditor. Significant increases in any of the significant unobservable inputs in isolation would not result in a materially lower fair value estimate. The interrelationship between these inputs is insignificant.

These financing arrangements are accounted for as a sale of assets under the provisions of ASC Topic No. 860, Transfers and Servicing. During the three months ended July 26, 2014 and July 27, 2013, we sold approximately $85,100 and $69,500, respectively, of contracts under these arrangements. Patterson retains servicing responsibilities under both agreements, for which we are paid a servicing fee. The servicing fees received by Patterson are considered adequate compensation for services rendered. Accordingly, no servicing asset or liability has been recorded. The agreements require us to maintain a minimum current ratio and maximum leverage ratio. Patterson was in compliance with the covenants at July 26, 2014.

Included in cash and cash equivalents in the consolidated balance sheets are approximately $30,177 and $28,152 as of July 26, 2014 and April 26, 2014, respectively, which represents cash collected from previously sold customer financing arrangements that have not yet been settled with the third party. Included in current receivables in the consolidated balance sheets are approximately $30,420, net of unearned income of $1,464, and $63,236, net of unearned income of $5,894, as of July 26, 2014 and April 26, 2014, respectively, of finance contracts not yet sold by Patterson. A total of $514,310 of finance contracts receivable sold under the agreements was outstanding at July 26, 2014. The deferred purchase price under the arrangements was approximately $83,506 and $84,750 as of July 26, 2014 and April 26, 2014, respectively. Since the internal financing program began in 1994, bad debt write-offs have amounted to less than one-percent of the loans originated.

 

10


Table of Contents

NOTE 8 SEGMENT REPORTING

Patterson Companies, Inc. is comprised of three reportable segments: dental supply, veterinary supply, and rehabilitation supply. Our reportable business segments are strategic business units that offer similar products and services to different customer bases. The dental supply segment provides a virtually complete range of consumable dental products, clinical and laboratory equipment and value-added services to dentists, dental laboratories, institutions and other dental healthcare providers throughout North America. The veterinary supply segment is a leading distributor of veterinary supplies, primarily to companion-pet (dogs, cats and other common household pets) and equine veterinary clinics. They also provide products and services used for the diagnosis, treatment and/or prevention of diseases in companion animals and equine throughout the United States and United Kingdom. The worldwide rehabilitation supply segment provides a comprehensive range of distributed and self-manufactured rehabilitation medical supplies and assistive products to acute care hospitals, long-term care facilities, rehabilitation clinics, dealers and schools.

We evaluate segment performance based on operating income. The corporate office general and administrative expenses are included in the dental supply segment and consist of home office support costs in areas such as information technology, finance, human resources and facilities. If these corporate expenses were allocated to the segments, the results would not be materially different as the dental segment would absorb a significant portion of these expenses. The cost to operate the distribution centers are allocated to the operating units based on the through-put of the unit.

The following table presents information about Patterson’s reportable segments:

 

     Three Months Ended  
     July 26, 2014      July 27, 2013  

Net sales

     

Dental supply

   $ 552,654       $ 554,233   

Veterinary supply

     386,302         199,683   

Rehabilitation supply

     120,573         126,209   
  

 

 

    

 

 

 

Consolidated net sales

   $ 1,059,529       $ 880,125   
  

 

 

    

 

 

 

Operating income

     

Dental supply

   $ 53,213       $ 55,490   

Veterinary supply

     13,987         9,047   

Rehabilitation supply

     17,554         16,744   
  

 

 

    

 

 

 

Consolidated operating income

   $ 84,754       $ 81,281   
  

 

 

    

 

 

 

The following table presents sales information by product for all of Patterson’s reportable segments:

 

     Three Months Ended  
     July 26,
2014
     July 27,
2013
 

Net sales

     

Consumable and printed products *

   $ 796,777       $ 609,949   

Equipment and software*

     179,429         196,143   

Other

     83,323         74,033   
  

 

 

    

 

 

 

Total

   $ 1,059,529       $ 880,125   
  

 

 

    

 

 

 

 

* Certain products, primarily dental hand pieces, were reclassified from equipment to consumables, to be consistent with the industry, in current and prior periods.

 

11


Table of Contents

NOTE 9 EMPLOYEE STOCK OWNERSHIP PLAN (ESOP)

During 1990, our Board of Directors adopted a leveraged ESOP. In fiscal 2002 and 2006, under the provisions of the plan and related financing arrangements, Patterson loaned the ESOP $12,612 (the “2002 note”) and $105,000 (the “2006 note”), respectively. The contribution to the ESOP, and the resulting allocation to employees, is determined annually by the Board of Directors following the close of the fiscal year. Shares of stock acquired by the plan are allocated to each participant who has completed 1,000 hours of service during the plan year. These shares are accounted for under ASC 718-40, Share-based Payments – Employee Stock Ownership Plans, and are not considered outstanding for computation of earnings per share until the shares are committed for release to the participants. We recognize expense based on the current fair value of the shares released to participants. As of July 26, 2014, a total of 2,736,969 of unallocated shares were held by the ESOP. The estimated ESOP expense recognized during the three months ended July 26, 2014 was $3,000 and during the three months ended July 27, 2013 was $5,700, respectively.

 

12


Table of Contents

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

Our first quarter fiscal 2015 financial information is summarized in this Management’s Discussion and Analysis, and the Condensed Consolidated Financial Statements and related Notes. The following background is essential to fully understanding our Company’s financial information.

Patterson operates a distribution business in three complementary markets: dental supply, veterinary supply and rehabilitation supply. Historically, our strategy for growth focused on internal growth and the acquisition of smaller distributors and businesses offering related products and services to the dental market. In fiscal 2002, we expanded our strategy to take advantage of a parallel growth opportunity in the veterinary supply market by acquiring the assets of J. A. Webster, Inc. on July 9, 2001. Effective January 1, 2013, Webster Veterinary Supply, Inc. changed its name to Patterson Veterinary Supply, Inc. Patterson added a third component to our business platform in fiscal 2004 when it entered the rehabilitation supply market with the acquisition of AbilityOne Products Corp. (“AbilityOne”) on September 12, 2003. AbilityOne is now known as Patterson Medical Holdings, Inc.

Operating margins of the veterinary business are considerably lower than the dental and rehabilitation supply businesses. While operating expenses run at a lower rate in the veterinary business, their gross margin is substantially lower due generally to pharmaceutical products sales, which have margins well below the average sundry product.

There are several important aspects of Patterson’s business that are useful in analyzing it, including: (1) market growth in the various markets in which we operate; (2) internal growth; (3) growth through acquisition; and (4) continued focus on controlling costs and enhancing efficiency. Management defines “internal growth” as the increase in net sales from period to period, excluding the impact of changes in currency exchange rates, and excluding the net sales, for a period of twelve months following the transaction date, of businesses we have acquired.

NVS Acquisition. On August 16, 2013 Patterson Companies, Inc. completed the acquisition of all the outstanding stock of National Veterinary Services Limited (“NVS”) from Dechra Pharmaceuticals, PLC (“NVS Acquisition”). NVS is the largest veterinary products distributor in the United Kingdom. Total cash consideration paid for NVS was £88.7 million (approximately $138.7 million). The acquisition is expected to be accretive to earnings by $0.02 to $0.03 per diluted share for the fiscal year ended April 25, 2015. The NVS business has lower gross margins and operating expenses than our historical businesses.

RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, the percentage of net sales represented by certain operational data.

 

     Three Months Ended  
     July 26,
2014
    July 27,
2013
 

Net sales

     100.0     100.0

Cost of sales

     72.0     68.0
  

 

 

   

 

 

 

Gross margin

     28.0     32.0

Operating expenses

     20.0     22.8
  

 

 

   

 

 

 

Operating income

     8.0     9.2

Other expense, net

     (0.7 %)      (1.0 %) 
  

 

 

   

 

 

 

Income before taxes

     7.3     8.2
  

 

 

   

 

 

 

Net income

     4.7     5.2
  

 

 

   

 

 

 

 

13


Table of Contents

QUARTER ENDED JULY 26, 2014 COMPARED TO QUARTER ENDED JULY 27, 2013.

Net Sales. Consolidated net sales for the three months ended July 26, 2014 (“Current Quarter”) were $1,059.6 million, a 20.4% increase from $880.1 million for the three months ended July 27, 2013 (“Prior Quarter”). Acquisitions contributed 19.8% to Current Quarter sales growth, and foreign exchange rate changes had an unfavorable impact to Current Quarter sales growth of 0.2%.

Sales of the Dental segment were $552.7 million, a 0.3% decrease from $554.2 million from the Prior Quarter. Current Period sales of consumables and printed office products increased 1.9%. Sales of dental equipment and software decreased 8.1% to $148.8 million due a strong comparable with prior year CEREC trade up programs. Sales of other services and products in the Dental segment increased 8.0% in the Current Quarter, from an increase in financing contracts and our Mercer acquisition in fiscal 2014.

Veterinary segment sales rose 93.5% to $386.3 million. Acquisitions contributed 86.9% to the current quarter sales growth. Excluding the NVS acquisition, consumables increased 7.1% due to new products in the parasiticide and heartworm categories as well as a shift in sales from our fourth quarter due to the late spring. Equipment and software sales decreased 8.5% as some projects were delayed into our second quarter. Sales of other services and products increased 11.9%.

Rehabilitation segment sales decreased 4.5% to $120.6 million, due to reduced sales from the non-core product lines that were divested in the second and fourth quarters of fiscal year 2014 which accounted for a decrease of 5.9%, offset by a favorable impact of 1.4% from changes in foreign exchange rates.

Gross Margins. Consolidated gross margin decreased 400 basis points from the Prior Quarter to 28.0%. The NVS Acquisition accounts for 430 basis points of the decrease, resulting in a comparable increase of 30 basis points from the Prior Quarter of 32.0%. The 30 basis point improvement is predominantly the result of the mix between product lines within the segments.

Operating Expenses. The consolidated operating expense ratio of 20.0% decreased 280 basis points from the Prior Quarter at 22.8%. The NVS Acquisition accounts for 320 basis points of the decrease. This results in a comparable operating expense rate of 23.2% versus 22.8% in the Prior Quarter. The deterioration in the operating expense rate resulted from the timing of the recognition of certain performance based compensation expense as well as the loss of leverage in the Dental segment due to the slight decline in total sales.

Operating Income. Current Quarter operating income was $84.8 million, or 8.0% of net sales. In the Prior Quarter, operating income was $81.3 million, or 9.2% of net sales. The decrease in the operating margin is due to the impacts from the NVS Acquisition which reduced operating margin by 110 basis points. The comparable operating margin rate is 9.1%.

Other (Expense) Income, Net. Net other expense was $7.3 million in the Current Quarter compared to $9.1 million in the Prior Quarter. Net other expense is comprised primarily of interest expense, partly offset by interest income. Foreign currency losses had a negative impact of $0.1 million compared to a $1.7 million negative impact in the Prior Quarter. Interest income of $1.6 million was up from $1.2 million in the Prior Quarter.

Income Tax Expense. The effective income tax rate for the Current Quarter was 35.1% compared to 36.4% in the Prior Quarter. The decrease in the current year rate is due primarily to the geographical shift in profits between domestic and international for the year. For the fiscal year, the income tax rate is expected to be in a range from 34.5% to 35.0%.

Net Income and Earnings Per Share. Net income was $50.3 million, compared to $45.9 million in the Prior Quarter. Earnings per diluted share was $0.50 in the Current Quarter compared to $0.45 in the Prior Quarter. Diluted shares outstanding in the Current Quarter were 100,182,000 compared to 101,919,000 in the Prior Quarter. The decrease in the share count is due to share repurchase activity over the past year. The Current Quarter’s cash dividend was $0.20 per common share compared to $0.16 in the Prior Quarter.

 

14


Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

Our cash flows from operations in the three-months ended July 26, 2014 were $68.8 million compared to $21.1 million in the Prior Period. The increase is primarily a result of timing and magnitude of income tax and accounts payable disbursements in the Prior Period that reduced cash flow from operations.

Net cash used in investing activities was $11.4 million in the Current Period compared to $5.6 million in the Prior Period primarily due to the investment in information systems. We expect to use a total of $45 million for capital expenditures in fiscal 2015, with our main investment is in information systems.

Cash used in financing activities during the Current Period was $63.8 million, including cash used for dividend payments of $20.1 million and common stock repurchases of $42.9 million. In the Prior Period, cash provided by financing activities was $84.8 million including a $135 million for a draw on our revolver for the purchase of NVS, offset by cash used for dividend payments of $29.8 million and stock repurchases of $22.2 million. The cash dividend outflow in the Prior Period included two quarterly dividend declarations due to the timing of the payment authorization for the previous fourth quarter dividend.

In fiscal 2014, we invested in three time deposits with total principal of $110,000 Canadian dollars. Our time deposit securities are classified as “held-to-maturity” securities and are carried at cost, adjusted for accrued interest and amortization. We have a $250 million note due in the fourth quarter of fiscal year 2015. We have both the intent and ability to refinance at that time, therefore we have classified this balance as long term debt on the balance sheet as of July 26, 2014 and April 26, 2014, respectively.

We expect funds generated from operations, existing cash balances and credit availability under existing debt facilities will be sufficient to meet our working capital needs and to finance anticipated expansion plans and strategic initiatives over the remainder of fiscal 2015.

As of July 26, 2014, $300 million was available under our $300 million revolving credit facility. Our current credit agreement expires in fiscal 2017.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. ASU No. 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605),” and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. We are evaluating the new standard, but do not, at this time, anticipate a material impact to the financial statements once implemented.

FACTORS THAT MAY AFFECT FUTURE OPERATING RESULTS

In our Form 10-K for the year ended April 26, 2014, we described material risk factors facing our business. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. As of the date of this report, there have been no material changes to the risk factors described in our Form 10-K.

 

15


Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes since April 26, 2014 in our market risk. For further information on market risk, refer to Item 7A in our 2014 Annual Report on Form 10-K filed June 25, 2014.

ITEM 4. CONTROLS AND PROCEDURES

Under the supervision and with the participation of our Company’s management, including our Company’s President and Chief Executive Officer (“CEO”) and its Chief Financial Officer (“CFO”), management evaluated the effectiveness of the design and operation of our Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of July 26, 2014. Based upon their evaluation of these disclosure controls and procedures, the CEO and CFO concluded that the disclosure controls and procedures were effective as of July 26, 2014.

There were no changes in our Company’s internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act) that occurred during the quarter ended July 26, 2014 that have materially affected, or are reasonably likely to materially affect, our Company’s internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 5. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On March 19, 2013, Patterson’s Board of Directors approved a new share repurchase plan that replaced the existing share repurchase plan. Under the new plan, up to 25 million shares may be purchased in open market transactions through March 19, 2018. As of July 26, 2014, a total of 20,941,993 shares remain available under the current repurchase authorization.

ITEM 6. EXHIBITS

The exhibits listed in the accompanying exhibit index are filed as part of this Quarterly Report on Form 10-Q.

All other items under Part II have been omitted because they are inapplicable or the answers are negative, or were previously reported in the 2014 Annual Report on Form 10-K filed June 25, 2014.

 

16


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    PATTERSON COMPANIES, INC.
    (Registrant)
Dated: September 4, 2014    
  By:  

/s/ R. Stephen Armstrong

    R. Stephen Armstrong
    Executive Vice President, Chief Financial Officer and Treasurer
    (Principal Financial Officer and Principal Accounting Officer)

 

17


Table of Contents

EXHIBIT INDEX

 

Exhibit

Number

  

Exhibit Description

31.1    Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2    Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a), under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32    Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101    Financials in XBRL format

 

18